PostDoc at SFB 824



The Technische Universität München (TUM) is seeking applications from highly motivated candidates for a Postdoc position in molecular imaging using novel PET-probes. The candidates will work in the DFG-funded Collaborative Research Center (SFB 824) entitled “Imaging for Selection, Monitoring and Individualization Cancer Therapies”.  The specific subproject in the SFB 824 is focussed on therapy assessment in prostate cancer using imaging surrogate markers for the PI3K-AKT-mTORC- and AR- pathway using novel probes for PET-imaging.

The candidate will be involved in applying established and developing new PET-probes and their applications to preclinical and clinical problems. The overall goal is to advance the diagnostic information for applications in prostate cancer. We aim to investigate PSMA-ligand PET as potential surrogate marker for activity of the PI3K-AKT-mTORC and AR-receptor axis and to develop and evaluate probes for differentiation of androgen-dependent and castration-resistant prostate cancer. Potential pre-targeting of PSMA under AR-targeted therapy as well as additive effect of radiosensitizer on PSMA radioligand therapy will be assessed. This approach may allow better patient selection and therapy decisions. The project will be developed in close collaboration with the Chair of Pharmaceutical Radiochemistry and the Department of Urology. The candidate will be supervised within a team of experienced scientists from TUM Nuclear Medicine (PD Dr. Matthias Eiber) and TUM Chair of Radiochemistry (Prof. Dr. Hans-Jürgen Wester). The TUM provides excellent infrastructure for conducting cutting-edge research in the field of molecular imaging (e.g. TranslaTUM as core facility for preclinical research, preclinical PET/CT and PET/MRI, state-of-the art radiochemistry).



We accept applications from candidates having a PhD with a strong background in natural and medical science with excellent degrees in biochemical or life sciences. Team spirit, capability for independent, self-motivated and analytical work, very good English and computer skills are required. Knowledge of physiopathology, practical experience in in-vivo preclinical animal research including preclinical imaging and analysing image data are highly recommended.


Our offer:

Postdoc candidates will be employed by the TUM (full position TVöD E13). The position is initially time-limited to the current funding period of the SF824, which is 4 years.


Application Details:

Applications should include curriculum vita, certificates and transcript of MA or doctoral degree, summary of the previous work, letter of motivation, and names of 2 references. Please send your application within one PDF-document to PD Dr. Matthias Eiber no later than October 1, 2017.



PD Dr. Matthias Eiber

phone: +49 89 4140 4549

Department of Nuclear Medicine, Klinikum rechts der Isar der TU München

Ismaningerstrasse 22, 81675 Munich, Germany


02.04.2020 09:00
In Vivo Magnetic Resonance – Recent Methods and Advances
01.04.2020 15:30
“Radiotheragnostics in Cancer Research – Terbium Sisters and Beyond”
22.05.2019 13:00
The curious case of the molecular subtypes of glioblastoma
28.03.2019 00:00
Girls´ Day-Angebot im TranslaTUM
06.03.2019 11:30
HSP110 as a therapeutic target in colorectal cancer: from crystals to drug selection
12.02.2019 17:00
Lecture “From yolk sac to neurodegeneration: the multiple facets if microgli” by